Innate Pharma S.A.
HealthcareNASDAQ:IPHA · NASDAQ Global Select
+$0.02 today
Vol 0.10M · Avg 0.07M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
226.7%
avg -54.9%
ROIC
-153.3%
avg -27.9%
ROA
-78.4%
avg -19.7%
Analysis
ROE is currently the strongest return metric at 226.7% versus its period average of -54.9%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jonathan E. Dickinson | Chief Executive Officer & Director | $1.08M | — | 58 | — | — |
Sonia Quaratino | Executive Vice President & Chief Medical Officer | $217,012.00 | — | 64 | — | — |
Yannis Morel | Executive Vice President & Chief Operating Officer | $188,816.00 | — | 53 | — | — |
Stephanie Cornen | Vice President of Investor Relations, Communication & Commercial Strategy | — | — | 39 | — | — |
Marc Bonneville | Founder | — | — | 66 | — | — |
Jean Jacques Fournié | Founder | — | — | — | — | — |
Frederic Lombard | Senior Vice President & Chief Financial Officer | — | — | 51 | — | — |
Odile Belzunce | VP, Chief of Compliance & Operations Officer and Interim Head of HR | — | — | 46 | — | — |
Alessandro Moretta | Founder | — | — | — | — | — |
François Romagné | Founder | — | — | 62 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +19.9% | +21.8% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +19.9% over three years. Forward estimates point to Revenue at +21.8% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Cybin Inc.
CYBN
$413.02M
Nuvectis Pharma, Inc.
NASDAQ:NVCT
$284.09M
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$283.43M
Compugen Ltd.
NASDAQ:CGEN
$192.89M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$109.08M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$105.29M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.67M
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
$49.65M
Applied Therapeutics, Inc.
APLT
$14.86M
Who manages IPHA?
Innate Pharma S.A. (IPHA) lists 10 active executives. The top listed executive is Jonathan E. Dickinson, Chief Executive Officer & Director.
Explore More
Continue the stock analysis
Jump to another research area for this company.